Literature DB >> 29387415

Significance of serum neural precursor cell-expressed developmentally downregulated protein 9 in melanoma.

Kayhan Erturk1, Faruk Tas1, Murat Serilmez1, Elif Bilgin1, Derya Duranyildiz1.   

Abstract

Neural precursor cell-expressed developmentally downregulated protein 9 (NEDD9) is a promoter for various cellular functions that result in tumorigenesis. The aim of the present study was to analyse the serum levels of NEDD9 in melanoma patients in order to evaluate its prognostic, predictive and diagnostic value. Data from 112 melanoma patients were retrospectively analyzed and ELISA assays were used to measure serum NEDD9 concentration. The median serum NEDD9 levels of the patients were significantly higher compared with those of the controls. Serum NEDD9 was not found to be associated with any of the clinicopathological parameters, and was also not found to be prognostic for survival in melanoma. Therefore, serum NEDD9 may be of diagnostic value in melanoma, but its usefulness in prognosis remains controversial. The important role of NEDD9 in tumor angiogenesis necessitates efforts to elucidate its interactions with the tumor microenvironment and its potential as a therapeutic target for malignancies.

Entities:  

Keywords:  diagnostic; melanoma; neural precursor cell-expressed developmentally downregulated protein 9; prognostic; serum

Year:  2017        PMID: 29387415      PMCID: PMC5769278          DOI: 10.3892/mco.2017.1493

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  29 in total

1.  Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment.

Authors:  S van der Flier; A Brinkman; M P Look; E M Kok; M E Meijer-van Gelder; J G Klijn; L C Dorssers; J A Foekens
Journal:  J Natl Cancer Inst       Date:  2000-01-19       Impact factor: 13.506

2.  Deregulation of HEF1 impairs M-phase progression by disrupting the RhoA activation cycle.

Authors:  Disha Dadke; Michael Jarnik; Elena N Pugacheva; Mahendra K Singh; Erica A Golemis
Journal:  Mol Biol Cell       Date:  2006-01-04       Impact factor: 4.138

Review 3.  p130Cas: a versatile scaffold in signaling networks.

Authors:  Paola Defilippi; Paola Di Stefano; Sara Cabodi
Journal:  Trends Cell Biol       Date:  2006-04-03       Impact factor: 20.808

Review 4.  Molecular requirements for epithelial-mesenchymal transition during tumor progression.

Authors:  Margit A Huber; Norbert Kraut; Hartmut Beug
Journal:  Curr Opin Cell Biol       Date:  2005-10       Impact factor: 8.382

Review 5.  Preclinical and clinical studies of the NEDD9 scaffold protein in cancer and other diseases.

Authors:  Elena Shagisultanova; Anna V Gaponova; Rashid Gabbasov; Emmanuelle Nicolas; Erica A Golemis
Journal:  Gene       Date:  2015-05-09       Impact factor: 3.688

6.  Expression of NEDD9 in pancreatic ductal adenocarcinoma and its clinical significance.

Authors:  Yu-Zheng Xue; Ying-Yue Sheng; Zong-Liang Liu; Zhe-Qiang Wei; Hai-Yan Cao; Yan-Min Wu; Yu-Feng Lu; Li-Hua Yu; Jian-Ping Li; Zhao-Shen Li
Journal:  Tumour Biol       Date:  2012-12-18

7.  NEDD9 overexpression correlates with the progression and prognosis in gastric carcinoma.

Authors:  Rongfeng Shi; Lei Wang; Tao Wang; Junfei Xu; Feiran Wang; Meirong Xu
Journal:  Med Oncol       Date:  2014-01-28       Impact factor: 3.064

8.  β-catenin inhibitor ICAT modulates the invasive motility of melanoma cells.

Authors:  Mélanie J Domingues; Florian Rambow; Bastien Job; Laura Papon; Wanguo Liu; Lionel Larue; Jacky Bonaventure
Journal:  Cancer Res       Date:  2014-02-10       Impact factor: 12.701

9.  NEDD9 promotes oncogenic signaling in mammary tumor development.

Authors:  Eugene Izumchenko; Mahendra K Singh; Olga V Plotnikova; Nadezhda Tikhmyanova; Joy L Little; Ilya G Serebriiskii; Sachiko Seo; Mineo Kurokawa; Brian L Egleston; Andres Klein-Szanto; Elena N Pugacheva; Richard R Hardy; Marina Wolfson; Denise C Connolly; Erica A Golemis
Journal:  Cancer Res       Date:  2009-09-08       Impact factor: 12.701

Review 10.  A new central scaffold for metastasis: parsing HEF1/Cas-L/NEDD9.

Authors:  Geraldine M O'Neill; Sachiko Seo; Ilya G Serebriiskii; Stuart R Lessin; Erica A Golemis
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

View more
  1 in total

1.  Circulating NEDD9 is increased in pulmonary arterial hypertension: A multicenter, retrospective analysis.

Authors:  Andriy O Samokhin; Steven Hsu; Paul B Yu; Aaron B Waxman; George A Alba; Bradley M Wertheim; C Danielle Hopkins; Frederick Bowman; Richard N Channick; Ivana Nikolic; Mariana Faria-Urbina; Paul M Hassoun; Jane A Leopold; Ryan J Tedford; Corey E Ventetuolo; Peter J Leary; Bradley A Maron
Journal:  J Heart Lung Transplant       Date:  2019-12-31       Impact factor: 10.247

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.